skip to main content
Idioma:
Resultados 1 2 3 4 5 next page
Mostrar Somente
Refinado por: assunto: Colorectal Cancer remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors
Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors
Material Type:
Artigo 		Adicionar ao Meu Espaço

Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors

García-Foncillas, Jesús ; Sunakawa, Yu ; Aderka, Dan ; Wainberg, Zev ; Ronga, Philippe ; Witzler, Pauline ; Stintzing, Sebastian

Frontiers in oncology, 2019-09, Vol.9, p.849-849 [Periódico revisado por pares]

Frontiers Research Foundation

Texto completo disponível

Citações Citado por
2
Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin
Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin
Material Type:
Artigo 		Adicionar ao Meu Espaço

Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin

Rao, Devika ; Mallick, Atrayee Basu ; Augustine, Titto ; Daroqui, Cecilia ; Jiffry, Jeeshan ; Merla, Amartej ; Chaudhary, Imran ; Seetharam, Raviraja ; Sood, Arjun ; Gajavelli, Srikanth ; Aparo, Santiago ; Rajdev, Lakshmi ; Kaubisch, Andreas ; Chuy, Jennifer ; Negassa, Abdissa ; Mariadason, John M ; Maitra, Radhashree ; Goel, Sanjay

Oncotarget, 2019-09, Vol.10 (53), p.5510-5522

United States: Impact Journals LLC

Texto completo disponível

Citações Citado por
3
SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer
SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer

Munemoto, Y. ; Nakamura, M. ; Takahashi, M. ; Kotaka, M. ; Kuroda, H. ; Kato, T. ; Minagawa, N. ; Noura, S. ; Fukunaga, M. ; Kuramochi, H. ; Touyama, T. ; Takahashi, T. ; Miwa, K. ; Satake, H. ; Kurosawa, S. ; Miura, T. ; Mishima, H. ; Sakamoto, J. ; Oba, K. ; Nagata, N.

European journal of cancer (1990), 2019-09, Vol.119, p.158-167 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
4
Desulfovibrio desulfuricans and its derived metabolites confer resistance to FOLFOX through METTL3Research in context
Desulfovibrio desulfuricans and its derived metabolites confer resistance to FOLFOX through METTL3Research in context
Material Type:
Artigo 		Adicionar ao Meu Espaço

Desulfovibrio desulfuricans and its derived metabolites confer resistance to FOLFOX through METTL3Research in context

Guifang Li ; Huan Liu ; Yangmeng Yu ; Qian Wang ; Chen Yang ; Yang Yan ; Fang Wang ; Yong Mao

EBioMedicine, 2024-04, Vol.102, p.105041 [Periódico revisado por pares]

Elsevier

Texto completo disponível

Citações Citado por
5
Prognostic Implications of Chemotherapy-Induced Neutropenia in Stage III Colorectal Cancer
Prognostic Implications of Chemotherapy-Induced Neutropenia in Stage III Colorectal Cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Prognostic Implications of Chemotherapy-Induced Neutropenia in Stage III Colorectal Cancer

Kim, Sungjin ; Kang, Sung IL ; Kim, Sohyun ; Kim, Jae Hwang

The Journal of surgical research, 2021-11, Vol.267, p.391-396 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
6
Fecal Microbiota Transplantation Prevents Intestinal Injury, Upregulation of Toll-Like Receptors, and 5-Fluorouracil/Oxaliplatin-Induced Toxicity in Colorectal Cancer
Fecal Microbiota Transplantation Prevents Intestinal Injury, Upregulation of Toll-Like Receptors, and 5-Fluorouracil/Oxaliplatin-Induced Toxicity in Colorectal Cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Fecal Microbiota Transplantation Prevents Intestinal Injury, Upregulation of Toll-Like Receptors, and 5-Fluorouracil/Oxaliplatin-Induced Toxicity in Colorectal Cancer

Chang, Ching-Wei ; Lee, Hung-Chang ; Li, Li-Hui ; Chiang Chiau, Jen-Shiu ; Wang, Tsang-En ; Chuang, Wei-Hung ; Chen, Ming-Jen ; Wang, Horng-Yuan ; Shih, Shou-Chuan ; Liu, Chia-Yuan ; Tsai, Tung-Hu ; Chen, Yu-Jen

International journal of molecular sciences, 2020-01, Vol.21 (2), p.386 [Periódico revisado por pares]

Switzerland: MDPI AG

Texto completo disponível

Citações Citado por
7
Curcumin Combined with FOLFOX Chemotherapy Is Safe and Tolerable in Patients with Metastatic Colorectal Cancer in a Randomized Phase IIa Trial
Curcumin Combined with FOLFOX Chemotherapy Is Safe and Tolerable in Patients with Metastatic Colorectal Cancer in a Randomized Phase IIa Trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Curcumin Combined with FOLFOX Chemotherapy Is Safe and Tolerable in Patients with Metastatic Colorectal Cancer in a Randomized Phase IIa Trial

Howells, Lynne M ; Iwuji, Chinenye O O ; Irving, Glen R B ; Barber, Shaun ; Walter, Harriet ; Sidat, Zahirah ; Griffin-Teall, Nicola ; Singh, Rajinder ; Foreman, Nalini ; Patel, Samita R ; Morgan, Bruno ; Steward, William P ; Gescher, Andreas ; Thomas, Anne L ; Brown, Karen

The Journal of nutrition, 2019-07, Vol.149 (7), p.1133-1139 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
8
High-accuracy prediction of colorectal cancer chemotherapy efficacy using machine learning applied to gene expression data
High-accuracy prediction of colorectal cancer chemotherapy efficacy using machine learning applied to gene expression data
Material Type:
Artigo 		Adicionar ao Meu Espaço

High-accuracy prediction of colorectal cancer chemotherapy efficacy using machine learning applied to gene expression data

Amniouel, Soukaina ; Jafri, Mohsin Saleet

Frontiers in physiology, 2024-01, Vol.14, p.1272206-1272206 [Periódico revisado por pares]

Switzerland: Frontiers Media S.A

Texto completo disponível

Citações Citado por
9
A Randomized Phase II Trial of mFOLFOX6 + Bevacizumab Alone or with AdCEA Vaccine + Avelumab Immunotherapy for Untreated Metastatic Colorectal Cancer
A Randomized Phase II Trial of mFOLFOX6 + Bevacizumab Alone or with AdCEA Vaccine + Avelumab Immunotherapy for Untreated Metastatic Colorectal Cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

A Randomized Phase II Trial of mFOLFOX6 + Bevacizumab Alone or with AdCEA Vaccine + Avelumab Immunotherapy for Untreated Metastatic Colorectal Cancer

Redman, Jason M ; Tsai, Yo-Ting ; Weinberg, Benjamin A ; Donahue, Renee N ; Gandhy, Shruti ; Gatti-Mays, Margaret E ; Abdul Sater, Houssein ; Bilusic, Marijo ; Cordes, Lisa M ; Steinberg, Seth M ; Marte, Jennifer L ; Jochems, Caroline ; Kim, Sunnie S ; Marshall, John L ; McMahon, Sheri ; Redmond, Erica ; Schlom, Jeffrey ; Gulley, James L ; Strauss, Julius

The oncologist (Dayton, Ohio), 2022-03, Vol.27 (3), p.198-209 [Periódico revisado por pares]

England: Oxford University Press

Texto completo disponível

Citações Citado por
10
Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial
Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial

Denda, Tadamichi ; Takashima, Atsuo ; Gamoh, Makio ; Iwanaga, Ichiro ; Komatsu, Yoshito ; Takahashi, Masanobu ; Nakamura, Masato ; Ohori, Hisatsugu ; Sakashita, Akiko ; Tsuda, Masahiro ; Kobayashi, Yoshimitsu ; Baba, Hideo ; Kotake, Masanori ; Ishioka, Chikashi ; Yamada, Yasuhide ; Sato, Atsushi ; Yuki, Satoshi ; Morita, Satoshi ; Takahashi, Shin ; Yamaguchi, Tatsuro ; Shimada, Ken

European journal of cancer (1990), 2021-09, Vol.154, p.296-306 [Periódico revisado por pares]

Oxford: Elsevier Ltd

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Recursos Online (220)
  2. Revistas revisadas por pares (212)

Refinar Meus Resultados

Tipo de Recurso 

  1. Artigos  (232)
  2. Reports  (1)
  3. Anais de Congresso  (1)
  4. Conjunto de Dados  (1)
  5. Livros  (1)
  6. Book Chapters  (1)
  7. Mais opções open sub menu

Data de Publicação 

De até
Refinar
  1. Antes de2006  (4)
  2. 2006Até2009  (29)
  3. 2010Até2013  (58)
  4. 2014Até2018  (65)
  5. Após 2018  (82)
  6. Mais opções open sub menu

Idioma 

  1. Inglês  (226)
  2. Japonês  (45)
  3. Chinês  (1)
  4. Francês  (1)
  5. Alemão  (1)
  6. Coreano  (1)
  7. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.